Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger E-box-binding homeobox 2 (ZEB2)
- Target
- ZEB2
- Molecular classification
- Transcription factor, DNA-binding protein, Zinc finger protein, Homeodomain protein
01
Overview
Zinc finger E-box-binding homeobox 2 (ZEB2) is a transcription factor containing multiple zinc finger domains and a homeodomain, encoded by the ZEB2 gene. ZEB2 acts primarily as a transcriptional repressor by binding to E-box sequences in DNA and interacting with corepressor complexes such as NuRD and CtBP. It regulates cell fate decisions, differentiation (notably in the nervous system, hematopoietic and immune cells), and is a key effector of TGF-β signaling, essential for embryogenesis and tissue homeostasis. Germline mutations in ZEB2 cause Mowat–Wilson syndrome, and its dysregulation contributes to developmental defects and cancer progression, often by promoting epithelial–mesenchymal transition and stem-like features in tumor cells.
- Other names
- ZEB2SIP1SMADIP1ZFHX1BZinc finger homeobox protein SIP1
02
Mechanism of action
Inhibition of ZEB2 expression to reverse EMT and tumor cell invasion; Targeting signaling pathways that regulate ZEB2, such as TGF-β, SMAD, or miR-200 family microRNA pathways
03
Biological functions
Transcriptional repression and activationRegulation of cell differentiationRegulation of epithelial–mesenchymal transition (EMT)Regulation of nervous system developmentHematopoietic differentiationRegulation of TGF-β signaling pathway
04
Disease associations
Mowat–Wilson syndrome (germline mutations)Hirschsprung’s disease (developmental deficiency)Cancer, especially solid tumors: hepatocellular carcinoma, myeloproliferative disease, leukemia (often through aberrant EMT and stemness features)Other neurodevelopmental syndromes
05
Safety considerations
Transcription factors like ZEB2 are generally considered “undruggable” due to lack of accessible/structured ligand binding sitesSystemic targeting may disrupt normal differentiation or development, causing toxicityPotential off-target developmental effects due to the role of ZEB2 in multiple organs and cell lineages, especially during development and differentiation
06
Interacting drugs
There are currently no approved therapeutic drugs that directly target ZEB2 as a molecular entity. Research focuses largely on upstream or downstream effectors, especially in cancer and fibrosis. Some small molecules under preclinical/experimental investigation may target transcriptional regulatory pathways that involve ZEB2, but no direct-interacting drugs are clinically established
07
Biomarkers
ZEB2 gene mutation analysis is a diagnostic marker for Mowat–Wilson syndromeZEB2 expression levels in tumors may serve as a prognosis biomarker in various cancers (for example, hepatocellular carcinoma)
Beyond the preview
Go deeper on Zinc finger E-box-binding homeobox 2 (ZEB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger E-box-binding homeobox 2 (ZEB2).